FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a method of inhibiting GH, GHR, STAT5, SOCS and c-fos, which involves identification of a subject having a disease or condition with changes in expression/activity of genes/proteins related to GH, human GHR, STAT5 and SOCS, or on which changes in expression/activity of genes/proteins related to human GH, GHR, STAT5 and SOCS, can have a beneficial effect; and administering a therapeutically effective amount of a compound selected from the group consisting of:
and their pharmaceutically acceptable salts.
EFFECT: technical result is novel activity of existing compounds and a method of inhibiting thereof, which can be used in medicine for treating cancer, diabetes, immunosuppression, Alzheimer's diseases and diseases and conditions, in respect of which cell and tissue regeneration has a favorable effect.
17 cl, 23 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NEW LIVER TARGETING ADENO-ASSOCIATED VIRAL VECTORS | 2019 |
|
RU2793735C2 |
| HUMANIZED ANTIBODY AGAINST IGF-1 RECEPTOR | 2019 |
|
RU2784079C1 |
| PEPTIDE DERIVATIVES - ANALOGS OF GRF OR THEIR NONTOXIC SALTS | 1990 |
|
RU2096416C1 |
| INDUCIBLE CHIMERIC CYTOKINE RECEPTORS | 2019 |
|
RU2826155C2 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| CHIMERIC CYTOKINE RECEPTOR | 2016 |
|
RU2826122C1 |
| TREATMENT OF DISEASES BY MEANS OF EXPRESSION OF ENZYME WITH DEOXYRIBONUCLEASE (DNase) ACTIVITY IN LIVER | 2019 |
|
RU2773691C2 |
| HUMAN INTERLEUKIN-2 VARIANT OR ITS DERIVATIVE | 2019 |
|
RU2799437C2 |
| TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES | 2018 |
|
RU2794170C2 |
